Healthcare [ 11/13 ] | Biotechnology [ 91/159 ]
NASDAQ | Common Stock
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Feb 14, 24 | -0.3 Decreased by -7.14% | -0.33 Increased by +9.09% |
| Nov 9, 23 | -0.35 Decreased by -9.37% | -0.34 Decreased by -2.94% |
| Aug 2, 23 | -0.33 Increased by +10.81% | -0.35 Increased by +5.71% |
| May 3, 23 | -0.4 Increased by +9.09% | -0.38 Decreased by -5.26% |
| Feb 14, 23 | -0.28 Increased by +34.88% | -0.35 Increased by +20% |
| Nov 3, 22 | -0.32 Increased by +20% | -0.38 Increased by +15.79% |
| Aug 3, 22 | -0.37 Decreased by -5.71% | -0.43 Increased by +13.95% |
| May 4, 22 | -0.44 Decreased by -51.72% | -0.46 Increased by +4.35% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 37.92 M Decreased by -20.72% | -50.3 M Decreased by -11.36% | Decreased by -132.65% Decreased by -40.47% |
| Jun 30, 23 | 48.93 M Increased by +12.06% | -47.81 M Increased by +7.4% | Decreased by -97.72% Increased by +17.36% |
| Mar 31, 23 | 37.65 M Decreased by -2.52% | -61.74 M Increased by +1.26% | Decreased by -163.99% Decreased by -1.29% |
| Dec 31, 22 | 55.2 M Increased by +45.53% | -24.52 M Increased by +60.08% | Decreased by -44.43% Increased by +72.57% |
| Sep 30, 22 | 47.83 M Increased by +21.19% | -45.17 M Increased by +19.34% | Decreased by -94.44% Increased by +33.44% |
| Jun 30, 22 | 43.66 M Increased by +13.39% | -51.63 M Decreased by -4.72% | Decreased by -118.25% Increased by +7.64% |
| Mar 31, 22 | 38.62 M Increased by +0.46% | -62.52 M Decreased by -53.84% | Decreased by -161.9% Decreased by -53.13% |
| Dec 31, 21 | 37.93 M Increased by +25.66% | -61.43 M Decreased by -37.83% | Decreased by -161.96% Decreased by -9.69% |
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.